Scynexis Inc. (NASDAQ:SCYX)’s share price traded down 7% during trading on Wednesday . The company traded as low as $3.40 and last traded at $3.43, with a volume of 583,007 shares trading hands. The stock had previously closed at $3.69.

A number of equities analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Scynexis in a report on Thursday, June 9th. Canaccord Genuity restated a “buy” rating on shares of Scynexis in a report on Thursday, June 9th. Brean Capital restated a “buy” rating on shares of Scynexis in a report on Monday, August 8th. Zacks Investment Research upgraded Scynexis from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a report on Friday, August 26th. Finally, Guggenheim assumed coverage on Scynexis in a report on Wednesday, August 17th. They set a “buy” rating and a $15.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $12.18.

The stock has a 50-day moving average price of $2.68 and a 200-day moving average price of $3.19. The stock’s market capitalization is $83.39 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/scynexis-inc-scyx-stock-price-down-7.html

Scynexis (NASDAQ:SCYX) last announced its earnings results on Monday, August 8th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.04. Scynexis had a negative return on equity of 73.13% and a negative net margin of 12,239.31%. Analysts forecast that Scynexis Inc. will post ($2.13) EPS for the current year.

In other Scynexis news, Director Patrick Machado acquired 40,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was bought at an average price of $2.94 per share, for a total transaction of $117,600.00. Following the acquisition, the director now directly owns 60,000 shares in the company, valued at $176,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gonzalez David Angulo acquired 36,950 shares of the company’s stock in a transaction that occurred on Thursday, June 30th. The shares were acquired at an average price of $2.22 per share, with a total value of $82,029.00. Following the acquisition, the insider now owns 8,850 shares in the company, valued at $19,647. The disclosure for this purchase can be found here. 3.91% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Granite Point Capital Management L.P. acquired a new position in Scynexis during the second quarter worth about $380,000. Private Advisor Group LLC raised its stake in shares of Scynexis by 100.0% in the second quarter. Private Advisor Group LLC now owns 200,000 shares of the company’s stock worth $434,000 after buying an additional 100,000 shares during the period. UBS Oconnor LLC purchased a new stake in shares of Scynexis during the second quarter worth $542,000. Sabby Management LLC purchased a new stake in shares of Scynexis during the second quarter worth $1,243,000. Finally, Deerfield Management Co. raised its stake in shares of Scynexis by 21.8% in the first quarter. Deerfield Management Co. now owns 848,000 shares of the company’s stock worth $3,417,000 after buying an additional 151,719 shares during the period. Institutional investors own 60.30% of the company’s stock.

Scynexis Company Profile

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

5 Day Chart for NASDAQ:SCYX

Receive News & Ratings for Scynexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scynexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.